Quick Answer
Summit Therapeutics Inc. reported Earnings Per Share Diluted of $1.44 (loss) per share for the year ending 2025.
- Summit Therapeutics Inc. showed a decrease of -364.5% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Summit Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2019 to 2025), Summit Therapeutics Inc.'s Earnings Per Share Diluted has declined by 328.6%.
- Historical annual values: Fiscal year 2025: $1.44 (loss) per share | Fiscal year 2024: $0.31 (loss) per share | Fiscal year 2023: $0.99 (loss) per share | Fiscal year 2022: $0.41 (loss) per share | Fiscal year 2021: $0.67 (loss) per share | Fiscal year 2020: $0.76 (loss) per share | Fiscal year 2019: $0.89 (loss) per share | Fiscal year 2019: $0.63 per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: